Nesivine Neusspray (Oxymetazoline Hydrochloride)

Oxymetazoline Hydrochloride, the active ingredient in Nesivine Neusspray, is an alpha‑adrenergic agonist presented as a nasal spray for nasal administration. It relieves nasal congestion associated with rhinitis, the common cold and other upper‑respiratory conditions, and is marketed throughout the European Union.

GNH USA supplies Nesivine Neusspray as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oxymetazoline acts on the nasal mucosa to reduce swelling and improve airflow in several common conditions.

Nasal congestion: reduces mucosal edema, allowing easier breathing. Rhinitis: alleviates congestion linked to allergic or non‑allergic rhinitis. Upper respiratory tract infection: provides symptomatic relief of nasal blockage during colds.

Adverse reactions may occur with use of nasal decongestant sprays.

Common Side Effects: - Nasal irritation or burning sensation - Dryness of the nasal mucosa - Sneezing or mild epistaxis - Headache or taste disturbance

Serious or Rare Side Effects: - Rebound nasal congestion (rhinitis medicamentosa) after prolonged use - Elevated blood pressure or hypertension - Tachycardia, arrhythmia, or palpitations - Severe nasal ulceration or anaphylactic reaction

Use Nesivine Neusspray according to professional guidance and observe the following safety measures.

Avoid prolonged use: limit treatment to no more than three consecutive days. Use with caution in hypertension: monitor blood pressure during therapy. Do not use in children under 6 years: safety not established for this age group. Avoid concurrent MAO inhibitors: risk of severe hypertensive episodes. Store at room temperature: keep below 25 °C, protect from moisture and direct sunlight.

Oxymetazoline may interact with other medicines that affect the cardiovascular or adrenergic systems.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension. - Sympathomimetic agents (e.g., pseudoephedrine): additive vasoconstriction. - Tricyclic antidepressants: increased cardiovascular effects.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: possible enhancement of blood‑pressure changes. - Other nasal decongestants: increased irritation risk. - Antihypertensive drugs: monitor for reduced efficacy.